CST
SPRY icon

Charles Schwab Trust’s ARS Pharmaceuticals SPRY Stock Holding History

Charles Schwab Trust’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,996,071
Closed -$21.9M – 169
2023
Q4 		$21.9M Sell
3,996,071
-250,000
-6% -$1.1M 2.16% 14
2023
Q3 		$16.1M Buy
+4,246,071
New +$27.9M 1.81% 14

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab Trust's SPRY Position: Q1 2024 in Review

Charles Schwab Trust sold out of ARS Pharmaceuticals (SPRY) in Q1 2024, closing a stake of 3,996,071 shares — an estimated $21.9M sold.

Charles Schwab Trust first reported a position in SPRY in Q3 2023 and held it in 2 quarters. The position peaked at $21.9M in Q4 2023. 113 funds tracked by Wall St. Rank hold SPRY as of Q1 2024.

  • Charles Schwab Trust reported no remaining ARS Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab Trust sold 3,996,071 ARS Pharmaceuticals shares in Q1 2024, an estimated $21.9M.
  • Charles Schwab Trust first reported a position in ARS Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Charles Schwab Trust's ARS Pharmaceuticals position peaked at $21.9M in Q4 2023.
  • 113 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2024.

Based on Charles Schwab Trust's 13F filing for Q1 2024, filed 12 Apr 2024.